Matches in SemOpenAlex for { <https://semopenalex.org/work/W2578149648> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2578149648 endingPage "488" @default.
- W2578149648 startingPage "488" @default.
- W2578149648 abstract "488 Background: There is still no effective treatment for the majority of patients suffering from peritoneal carcinomatosis (PC) of colon cancer. Palliative chemotherapy (CHEM) had limited efficacy. Cytoreductive surgery and hyperthermic chemoperfusion (HIPEC) showed promising results, but was manageable in early stage PC patients only. Catumaxomab therapy (CATU) offers a new option for intraperitoneal treatment in all stages of PC. Aim of the study was to evaluate CATU therapy in comparison to HIPEC and systemic therapy. Methods: Between 2005 and 2008, 76 patients suffering from PC of colon cancer were included and treated with systemic chemotherapy alone (35), HIPEC +/- systemic chemotherapy (21) and CATU +/- chemotherapy (22). All patients were assessed for therapy-related severe side effects, incidence of intestinal obstruction-ileus and ascites and for overall survival. Results: Grade IV side effects were observed in 9.1% of CATU patients, 14.3% after HIPEC and 5.7% after CHEM. Ascites was found in not a single patient after CATU vs. one patient after HIPEC (4.5%) and 7 patients after chemotherapy (20%, p<0.03). Intestinal obstruction was found in 22.7% of patients after CATU vs. 14.3% after HIPEC and in 42.9% of patients after chemotherapy (p<0.04). In comparison to systemic chemotherapy, overall survival was significantly increased after CATU (15.2 months, p=0.03) and HIPEC (20.1 months, p=0.02; median follow-up 17 months). Conclusions: Catumaxomab therapy of patients with PC from colon cancer was associated with a preventive effect for accumulation of malignant ascites and intestinal obstruction. Patients receiving CATU or HIPEC therapy concepts showed a survival benefit compared to systemic chemotherapy alone. Therapy strategies containing intraperitoneal catumaxomab treatment may be beneficial in patients with PC from colon cancer, even in advanced PC disease, when HIPEC was not feasible. [Table: see text]" @default.
- W2578149648 created "2017-01-26" @default.
- W2578149648 creator A5005247091 @default.
- W2578149648 creator A5055887612 @default.
- W2578149648 date "2011-02-01" @default.
- W2578149648 modified "2023-10-18" @default.
- W2578149648 title "Catumaxomab therapy in peritoneal carcinomatosis from colon cancer: Clinical benefit in comparison to systemic chemotherapy alone and cytoreductive surgery/hyperthermic chemoperfusion." @default.
- W2578149648 doi "https://doi.org/10.1200/jco.2011.29.4_suppl.488" @default.
- W2578149648 hasPublicationYear "2011" @default.
- W2578149648 type Work @default.
- W2578149648 sameAs 2578149648 @default.
- W2578149648 citedByCount "1" @default.
- W2578149648 countsByYear W25781496482012 @default.
- W2578149648 crossrefType "journal-article" @default.
- W2578149648 hasAuthorship W2578149648A5005247091 @default.
- W2578149648 hasAuthorship W2578149648A5055887612 @default.
- W2578149648 hasConcept C121608353 @default.
- W2578149648 hasConcept C126322002 @default.
- W2578149648 hasConcept C141071460 @default.
- W2578149648 hasConcept C143998085 @default.
- W2578149648 hasConcept C185926286 @default.
- W2578149648 hasConcept C2776694085 @default.
- W2578149648 hasConcept C2777125728 @default.
- W2578149648 hasConcept C2779458272 @default.
- W2578149648 hasConcept C2779787475 @default.
- W2578149648 hasConcept C2780427987 @default.
- W2578149648 hasConcept C2780496750 @default.
- W2578149648 hasConcept C2991818862 @default.
- W2578149648 hasConcept C2994223192 @default.
- W2578149648 hasConcept C526805850 @default.
- W2578149648 hasConcept C530470458 @default.
- W2578149648 hasConcept C71924100 @default.
- W2578149648 hasConcept C90924648 @default.
- W2578149648 hasConceptScore W2578149648C121608353 @default.
- W2578149648 hasConceptScore W2578149648C126322002 @default.
- W2578149648 hasConceptScore W2578149648C141071460 @default.
- W2578149648 hasConceptScore W2578149648C143998085 @default.
- W2578149648 hasConceptScore W2578149648C185926286 @default.
- W2578149648 hasConceptScore W2578149648C2776694085 @default.
- W2578149648 hasConceptScore W2578149648C2777125728 @default.
- W2578149648 hasConceptScore W2578149648C2779458272 @default.
- W2578149648 hasConceptScore W2578149648C2779787475 @default.
- W2578149648 hasConceptScore W2578149648C2780427987 @default.
- W2578149648 hasConceptScore W2578149648C2780496750 @default.
- W2578149648 hasConceptScore W2578149648C2991818862 @default.
- W2578149648 hasConceptScore W2578149648C2994223192 @default.
- W2578149648 hasConceptScore W2578149648C526805850 @default.
- W2578149648 hasConceptScore W2578149648C530470458 @default.
- W2578149648 hasConceptScore W2578149648C71924100 @default.
- W2578149648 hasConceptScore W2578149648C90924648 @default.
- W2578149648 hasIssue "4_suppl" @default.
- W2578149648 hasLocation W25781496481 @default.
- W2578149648 hasOpenAccess W2578149648 @default.
- W2578149648 hasPrimaryLocation W25781496481 @default.
- W2578149648 hasRelatedWork W1966712075 @default.
- W2578149648 hasRelatedWork W2081416064 @default.
- W2578149648 hasRelatedWork W2082594509 @default.
- W2578149648 hasRelatedWork W2578149648 @default.
- W2578149648 hasRelatedWork W2761991271 @default.
- W2578149648 hasRelatedWork W2891788805 @default.
- W2578149648 hasRelatedWork W2943603223 @default.
- W2578149648 hasRelatedWork W3164978819 @default.
- W2578149648 hasRelatedWork W4253896473 @default.
- W2578149648 hasRelatedWork W4281707746 @default.
- W2578149648 hasVolume "29" @default.
- W2578149648 isParatext "false" @default.
- W2578149648 isRetracted "false" @default.
- W2578149648 magId "2578149648" @default.
- W2578149648 workType "article" @default.